Inclusion Criteria:

- adult patients, >=18 years of age;

- advanced and/or metastatic cancer not amenable to standard therapy;

- any solid tumor type (Part 1); malignant melanoma or other responsive tumor type
(Part 2);

- measurable and/or evaluable disease (Part 1); >=1 measurable lesion (Part 2);

- ECOG performance status 0-2.

Exclusion Criteria:

- prior chemotherapy, radiotherapy or immunotherapy within 28 days of first receipt of
study drug;

- prior corticosteroids as anti-cancer therapy within 14 days of first receipt of study
drug;

- active CNS lesions;

- acute or chronic infection.